Insight Molecular Diagnostics expects about $0.25M Q2 2026 revenue while projecting second-quarter cash burn above $9M (NASDAQ:IMDX)May 14, 2026
Share Facebook Twitter LinkedIn Pinterest Email Internal equity valuation of $19bn in October would be vastly lower today